Product Code: RP-ID-10151874 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151874
Market Overview:
Global 3D Bioprinting in Medical Industry Market Research 2030
"In 2021, the global 3D bioprinting market is estimated to be worth USD ~2 billion, and it is expected to grow at a compound annual growth rate (CAGR) of ~17% from 2022 to 2030. The growth of this market is attributed to the limited number of organ donors and an aging population suffering from chronic respiratory diseases. Increasing R&D investment, technological progress, and increasing incidence of chronic diseases are other important influencing attributes that may drive market growth during the forecast period. Fatigue and overloaded sanitation system.
Therefore, in response to the increase in coronavirus cases, various 3D bioprinting communities are responding to the global crisis by providing their own skills to reduce the burden on the supply chain and the government. , There has been a shortage of materials for medical professionals and the general public. One of the biggest problems is the inability to obtain COVID-19 test kits. Therefore, several 3D bioprinting companies are manufacturing 3D printers and related software on a large scale.​​​​ For example, Formlabs, a Massachusetts-based company, now produces 100,000 nasal swabs per day for COVID-19 testing. Due to the increase in COVID-19 cases, the demand for 3D bioprinters continues to increase, and the 3D bioprinting market is expected to grow exponentially.
The coronavirus pandemic has also accelerated the development of drug and vaccine testing, and how scientists can use new technology to test patients for safety after preclinical trials are completed. With the increase in COVID-19 cases, the medical community is also facing a shortage of ventilators and ventilators. 3D bioprinting technology is helping to make respirators and ventilators to overcome the shortage of these devices. Recently, 3D bioprinting company CLECELL used its proprietary U-FAB 3D printer and other bioprinting technologies to create respiratory epithelial models. Respiratory tract epithelium is a tissue distributed in most of the respiratory tract. This epithelial cell acts as a barrier against pathogens and foreign particles.
However, it can also prevent infection and tissue damage with the help of a mucociliary lifter. Therefore, as the demand for this respiratory epithelial model continues to increase, the 3D bioprinting market is expected to grow. Due to these innovations, the market is expected to grow further during the forecast period. Many biotherapy companies are using 3D bioprinting technology to accelerate COVID-19 research. For example, Viscient Biosciences uses 3D bioprinting technology to create lung tissue, supports research on viral infectivity, and helps find effective treatments for SARS-CoV-2 (the new coronavirus that causes COVID-19).
The Wyss Institute at Harvard University, in collaboration with healthcare, industry partners, and other research institutions, designed a fully injection molded nasopharyngeal swab. With the increasing popularity of Covid-19, 3D bioprinting is experiencing large-scale demand. Therefore, many pharmaceutical and biopharmaceutical participants help medical staff, doctors, and scientists in every possible way. For example, Stratasys is one of the leading 3D printer manufacturers in the United States, which manufactures masks with the help of 3D bioprinters. As of March 2020, they have shipped 100,000 masks to the United States.
Technical insight:
The inkjet-based part dominates the 3D bioprinting market and will occupy the largest revenue share of 35% in 2020, because it can use biotin and other biological materials to print complex living organs or tissues on the substrate. The widespread adoption of inkjet printing in the medical field has promoted the growth of this market segment.
This article introduces the research trend of inkjet printing as a bio-applicable technology, especially in the fields of tissue engineering and drug delivery systems. Due to increased demand and increased reliability, this market segment is expected to witness significant growth during the forecast period. During the forecast period, the maglev part is expected to grow at the fastest compound annual growth rate of 17.0%. The lucrative growth can be attributed to the profitability associated with the technology.
With its advanced functions, higher speed and accuracy, magnetic levitation technology is expected to solve more than 80.0% of errors in 3D bioprinting. These bioprinters are also used for toxicity testing, blood vessel muscle printing and human cell regeneration. For example, BioAssay has developed a tissue-like structure with the help of a device based on magnetic levitation. Due to the rapid increase in the use of newer technologies, magnetic levitation-based devices are more likely to experience slow growth during the forecast period.
Application type information :
The medical sector dominates the 3D bioprinting market and will account for the largest revenue share in 2020 at 35%. The compound annual growth rate of this sector is expected to be 21% during the forecast period. The widespread use of pills to treat various chronic diseases is driving the growth of the bio 3D printing market.
In addition, the increasing demand for drugs and the profitable applications of biopharmaceuticals using this technology are further promoting the development of this market segment. With more and more participants in the pharmaceutical industry, the demand for pills is also increasing. Millions of people around the world regularly use medicinal capsules and pills.
Therefore, this market segment is expected to achieve lucrative growth during the forecast period. During the forecast period, the tissue and organ generation sub-segment is expected to witness the fastest compound annual growth rate of 18% in the 3D bioprinting market. 3D bioprinting is more widely used in regenerative medicine to meet the regeneration needs of organs and tissues suitable for transplantation.
As the incidence of COVID-19 disease increases, so does the demand for tissue and organ production. For this reason, it is expected that the tissue and organ production part will experience exponential growth during the forecast period. The increasing number of COVID -19 cases worldwide is expected to provide major market players with new growth avenues. Several players in the 3D bioprinting market are developing new technologies that can overcome this pandemic effect and produce a vaccine to treat COVID-19.
Regional insight:
North America dominates the 3D bioprinting market and will account for the largest revenue share in 2020 at 33%. It is estimated that during the forecast period, the increasing integration of IT into the healthcare industry will stimulate market growth. According to the World Metrology Report 2021, as of January 13, 2021, approximately 23,369,732 active Covid-19 cases have been reported in the United States alone. More than 50 vaccine candidates are currently being tested.
The government is increasing investment in research and development in order to develop a vaccine against this disease. For this reason, the demand for 3D bioprinting continues to grow, as the technology has been approved for drug testing and organ transplantation. In the Asia-Pacific region, this market accounted for 22% of revenue share in 2020 and is expected to continue to dominate during the forecast period. Due to the increasing incidence of COVID-19 cases and increasing government investment in research and development, Japan and China have the largest revenue share in the region. According to the 2021 World Instrument Report, approximately 87,706 active cases of COVID-19 have been reported. Covid -19 is in China until January 13, 2021. In addition, the increase in mortality due to COVID-19 and the shortage of organ donors are expected to boost the market in the region.
Key companies and market share insights:
Key companies emphasize R&D to develop technologically advanced applications to gain a competitive advantage. For example, in November 2019, CELLINK developed Bio X6, the most advanced 3D bioprinting device, and Lumen X, which produces vascular structures. In addition, Swedish Fluicell also launched a 3D and 2D shape high-resolution bioprinting technology called Biopixlar. This 3D bioprinter creates a complex tissue-like structure through which the positioning of individual cells can be controlled. It contains a novel feature that allows the user to control the system.
The two companies are establishing partnerships, mergers and acquisitions with the aim of strengthening their application portfolio, manufacturing capabilities and providing competitive differentiation. For example, in November 2019, BASF Co., Ltd. acquired 3D printing service provider Sculpteo. The acquisition is expected to help BASF market and establish new industrial 3D printing materials faster. Some of the major players in the 3D bioprinting market include: Envisiontec, Inc. Organovo Holdings, Inc. Inventia Life Science PTY LTD PoietisVivax Bio, LLC AleviCyfuse Biomedical K.K.3D Bioprinting Solutions Celllink GlobalRegemat 3D S.L.
Market segments covered by the report:
The report forecasts global, regional and national revenue growth, and analyzes the latest industry trends in each sub-segment from 2022-2030. For the purpose of this research, Kenneth Research reports on the global 3D bioprinting market based on technology, application and region: technology outlook (revenue, million dollars, 2022-2030) magnetic levitation inkjet-based injector based on laser other application prospects (Income, millions of dollars,2022-2030)) Medical tissue and organ production, medical pills, prosthetics and implants, other dental biosensors, personal/consumer product testing, Bioinks food and animal products"
Related Reports
Proof of Quality & Reliability
